{"url_path":"/sec/isco/10-q/2026/item-5","section_key":"item-5","section_title":"Item 5 Other Information","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-14","source_url":"https://www.sec.gov/Archives/edgar/data/1355790/0001193125-26-223926-index.html","accession_number":"0001193125-26-223926","cik":"0001355790","ticker":"ISCO","issuer_name":"International Stem Cell CORP","edgar_url":"https://www.sec.gov/Archives/edgar/data/1355790/0001193125-26-223926-index.html","primary_entity_key":"0001355790","primary_entity_name":"International Stem Cell CORP"},"word_count":55,"has_tables":true,"body_markdown":"Item 5. Other Information\n\nDuring the quarter ended March 31, 2026, none of our directors or officers (as defined in Rule 16a-1(f) of the Securities Exchange Act of 1934) adopted, terminated or modified a Rule 10b5-1 trading arrangement or non-Rule 10b5-1 trading arrangement (as such terms are defined in Item 408 of Regulation S-K).\n\n25"}